Clinical trials: Covid19- Coronavirus- Sars-cov-2
Cardiomyopathies
Myocardial Involvement of Severe Acute Respiratory Syndrome-Cov-2 (Covid19) Infected Patients
The effects of severe acute respiratory syndrome SARS-Cov-2 (Covid-19) on the myocardium and their role in the clinical course of infected patients are still unknown.
- Trial name
- COCARDE (NCT04358952)
- Testing
- Global Longitudinal Strain
- Where
- France
- Volunteers
- 122 people
- Sponsor
- University Hospital, Toulouse
SARS-CoV-2
Prognostic Factors of COVID19
COVID-19 is an emerging disease, for which no specific treatment options are currently available. Since the end of February 2020, and due to a SARS-CoV-2 superspreading event (religious meeting), the Strasbourg University…
- Trial name
- Covid-HUS (NCT04405726)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Strasbourg, France
Neuromuscular Blockade, Human Characteristics
Sparing in Neuromuscular Blockade in COVID 19 ICU
This is a retrospective case-controlled study of the effect of the use of a neuromuscular blockade (NMB) monitor on the consumption of NMB agents in patients under mechanical ventilation in the context of COVID-19.
- Conditions
- Neuromuscular Blockade, Human Characteristics, Complication of Medical Care, Intensive Care Unit Acquired Weakness
- Trial name
- TOF-COVID (NCT04459533)
- Testing
- TOF protocol
- Where
- France
- Volunteers
- 250 people
- Sponsor
- Hospices Civils de Lyon
Pneumococcal Disease, COVID-19
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone
- Conditions
- Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
- Trial name
- NCT04887948
- Testing
- 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
- Where
- 27 sites in United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19, Vaccine Adverse Reaction
COVID19 Vaccine in SOT Adult Recipients
Background: ISHLT and AASLD guidelines recommend SARS-CoV2 vaccination in all individuals undergoing lung and liver transplantation, but there are currently scarce data on the safety and efficacy of these vaccines in this…
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine Response Impaired, Vaccine Reaction
- Trial name
- COVID19_VaxSOT (NCT05116748)
- Testing
- COVID19 mRNA vaccine
- Where
- Italy
- Volunteers
- 364 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
COVID-19
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19.
- Trial name
- HERO-HCQ (NCT04334148)
- Testing
- Hydroxychloroquine
- Where
- 34 sites in United States
- Volunteers
- 1,360 people, healthy volunteers welcome
- Sponsor
- Adrian Hernandez
SARS-CoV-2 Infection, Coronavirus Disease 2019 (COVID-19)
COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older
The most recently discovered coronavirus (SARS-CoV-2) may cause illness in humans ranging from the common cold to serious illness, also referred to as Coronavirus disease 2019 (COVID-19).
- Trial name
- CV-NCOV-011 (NCT04848467)
- Testing
- SARS-CoV-2 mRNA Vaccine (CVnCoV), Quadrivalent influenza vaccine (QIV)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bayer
Covid19
Early Detection of COVID-19 Using Breath Analysis
EARLY DETECTION OF COVID-19 USING BREATH ANALYSIS- FIRST CROSS-SECTIONAL STUDY
- Trial name
- COVID-19 (NCT04602884)
- Testing
- Breath biopsy sampling using the ReCIVA Breath Sampler
- Where
- Israel
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Scentech Medical Technologies Ltd
Covid19
Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.
Phase 2b clinical trial to evaluate the safety and efficacy of intranasal application of GX-03 as a treatment and prevention for COVID-19.
- Trial name
- NCT04951349
- Testing
- GX-03, Petrolatum ointment
- Where
- 3 sites in Panama
- Volunteers
- 85 people
- Sponsor
- Turn Therapeutics
Long-COVID
Long-term COVID and Rehabilitation
The proposed focuses on improving both morbidity and mortality in older Veterans and those recovering from COVID-19 by developing rehabilitation therapies to augment vascular endothelial function by combating the oxidative stress…
- Trial name
- NCT05373043
- Testing
- Mitoquinone
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
SARS-CoV-2 Seroprevalence
ANC COVID-19 Surveillance
The purpose of this observational study is to determine the seroprevalence of SARS-CoV-2 antibodies in the community with pregnant women aged 15-49 years attending first antenatal care as the sentinel population.
- Trial name
- NCT07021807
- Where
- Zambia
- Volunteers
- 9,111 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Respiratory Failure
Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS
This study assesses the clinical effectiveness of mammalian target of rapamycin (mTOR) inhibition with rapamycin in minimizing or decreasing the severity of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) in…
- Conditions
- Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Respiratory Failure, Sars-CoV2
- Trial name
- RAPA-CARDS (NCT04482712)
- Testing
- Rapamycin
- Where
- 2 sites in United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
COVID-19
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-1283.222 versus mRNA-1273.222 (Part 1) and mRNA-1283.815 versus mRNA-1273.815…
- Trial name
- NextCOVE (NCT05815498)
- Testing
- mRNA-1283.222, mRNA-1273.222, mRNA-1283.815
- Where
- 230 sites in United States, Canada and 2 more
- Volunteers
- 13,553 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Risk Factors for COVID-19 Outcomes in Elderly Populations
Direct and Indirect Impact of COVID-19 In Older Populations
This study propose to describe risk factors for acute and long term mortality of COVID 19 in patients up to 70 years old.
- Trial name
- COVID-OLD (NCT04381312)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Grenoble
Neuroendocrine Tumors, COVID-19
Registry on NEN Patients and COVID-19
A huge number of initiatives about COVID-19 are ongoing and a growing number of publications regard the correlation between cancer patients in general and SARS-CoV-2 infection.
- Trial name
- NCT04444401
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- European Institute of Oncology
Coronavirus Disease 2019 (COVID-19)
Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC)…
- Trial name
- NCT04409509
- Testing
- Garadacimab, Factor XIIa Antagonist Monoclonal Antibody
- Where
- 14 sites in United States
- Volunteers
- 124 people
- Sponsor
- CSL Behring
Infection, Respiratory Tract
Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic
The aim of this study is to investigate whether vaccination of healthcare professionals with VPM1002 could reduce the number of days absent from work due to respiratory disease (with or without documented SARS-CoV-2 infection).
- Trial name
- NCT04387409
- Testing
- VPM1002
- Where
- 3 sites in Germany
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Serum Life Science Europe GmbH
Novel Coronavirus-induced Lung Fibrosis
Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia
The antifibrotic agents, namely pirfenidone and nintedanib have been found to be effective in the treatment of idiopathic pulmonary fibrosis (IPF).
- Trial name
- PINCER (NCT04856111)
- Testing
- Pirfenidone, Nintedanib
- Where
- India
- Volunteers
- 48 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
COVID-19
Safety and Efficacy of Ruxolitinib for COVID-19
This study plans to learn more about the effects of a medicine called ruxolitinib on the progression of COVID-19 (coronavirus disease of 2019), the medical condition caused by the Severe Acute Respiratory Syndrome Coronavirus 2…
- Trial name
- NCT04348071
- Testing
- Ruxolitinib
- Sponsor
- University of Colorado, Denver
COVID-19
COVID-19: A Prevalence Study of Two ART Centres After the Pandemic Lockdown in the USA (COVID-19 Free Clinics)
In late December 2019, a new coronavirus strain emerged causing coronavirus disease 2019 (COVID19). Since then, COVID19 has become a global pandemic outbreak being declared a "public health emergency of international concern" by…
- Trial name
- NCT04466644
- Testing
- ELISA, RT-PCR
- Where
- 2 sites in United States
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Igenomix
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.